About Dylan Sammut
Articles Written by Dylan Sammut
Gilead Bets $21 Billion on Oncology Market
Gilead Sciences, Inc. (NASDAQ: GILD) kicked off this week with a multi-billion acquisition of Immunomedics (NASDAQ: IMMU). The pharmaceutical giant reached an agreement to buy Immunomedics for $21 billion, or $88 per share, a 108% premium to Immunomedics’ closing... Read More »
Kai Medical Labs Acquired by Empower Clinics to Ramp Up COVID Testing
Empower Clinics Inc., a vertically integrated health and wellness company, has jumped into the healthcare M&A market. Last week, the company acquired Kai Medical Laboratory, LLC for an undisclosed sum. Kai Medical Laboratory is a high-complexity CLIA- and... Read More »
Behavioral Health Care M&A Survived the Summer
The Behavioral Health Care M&A market and industry have experienced one effect from COVID-19 that most other healthcare services have not and that is an increase in patients seeking treatment. The pandemic’s impact on jobs, social interactions and myriad other... Read More »
How Has COVID-19 Shaped the Healthcare M&A Market?
Examining the healthcare M&A market in 2019 may seem like a strange endeavor since, for many of us, it feels like an entirely different era. But there’s value in analyzing how the healthcare M&A market in August 2020 differed from the one in August 2019, even... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
